Genetic Engineering of Oncolytic Viruses for Cancer Therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

This chapter will review the recent clinical application of therapeutic viruses for the treatment of cancer. While certain viruses have been known to have the ability to kill cancer cells, it is only from 1990 to 2010 that technological advances in viral culture methodology and molecular engineering have made clinical translation possible. Many different viruses are in clinical testing currently, and several are being tested in advanced efficacy trials. While these agents have been abundantly safe, there has been mixed efficacy seen and somewhat more modest results than expected when compared to preclinical models. Therefore, this chapter aims to review the current status of oncolytic viruses and the molecular approaches that are being utilized to improve upon the platform of oncolytic virotherapy for clinical translation.

Original languageEnglish (US)
Title of host publicationTranslating Gene Therapy to the Clinic
Subtitle of host publicationTechniques and Approaches
PublisherElsevier Inc.
Pages261-279
Number of pages19
ISBN (Electronic)9780128005644
ISBN (Print)9780128005637
DOIs
StatePublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved..

Keywords

  • Adenovirus
  • Adoptive immunotherapy
  • Cytokines
  • Measles
  • Oncolytic

Fingerprint

Dive into the research topics of 'Genetic Engineering of Oncolytic Viruses for Cancer Therapy'. Together they form a unique fingerprint.

Cite this